Dolby Laboratories DLB
- Market cap
- $5.9B
- PE
- 26.7×
- 10y median 31.2×
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 4.3×
- EV/EBIT
- 22.1×
- Revenue, 12 months
- $1.4B
- +1% on a year ago
- Net margin
- 16.7%
- Free cash flow yield
- 6.7%
Dolby Laboratories trades at 26.7× trailing earnings, cheaper than 74% of the last ten years. Revenue was $1.4B over the last twelve months, up 1% on a year earlier with a 17% net margin.
Charts
Financials
| Income statement | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $290.6M+4% | $315.6M−6% | $364.5M−3% | $288.8M−3% | $304.8M+5% | $357M+13% | $369.6M+1% | $315.5M+9% | $307M+1% | $346.7M−3% | $395.6M+7% | $305M−3% | |
| Cost of revenue | $35.6M−4% | $32.1M−7% | $38.8M−6% | $35.7M−14% | $34M−4% | $40.8M+27% | $35.8M−8% | $44M+23% | $39.5M+16% | $43.2M+6% | $44.7M+25% | $40.3M−8% |
| Gross profit | $255M+6% | $283.5M−6% | $325.7M−3% | $253.2M−1% | $270.8M+6% | $316.2M+12% | $333.7M+2% | $271.5M+7% | $267.5M−1% | $303.5M−4% | $350.9M+5% | $264.7M−3% |
| R&D | $70.4M+14% | $67M+4% | $62.5M−8% | $65.5M−5% | $68.6M−3% | $66.6M−1% | $61.7M−1% | $66M+1% | $67.5M−2% | $69.1M+4% | $63.7M+3% | $65.7M−0% |
| SG&A | $157.5M+7% | $144.2M+1% | $156.8M−1% | $146.8M−6% | $157.1M−0% | $164.5M+14% | $160M+2% | $158.5M+8% | $164.2M+5% | $161.8M−2% | $172.1M+8% | $160.7M+1% |
| −$3.5M | $66.2M−30% | $109M−0% | $36.8M+131% | $46.4M | $79.9M+21% | $107.8M−1% | $47.6M+30% | $29.7M−36% | $62.2M−22% | $112.9M+5% | $34.3M−28% | |
| Interest expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Pre-tax income | $9M−71% | $80.8M−19% | $121.7M+4% | $50.2M+111% | $59.7M+561% | $86.1M+7% | $120.3M−1% | $55.5M+11% | $41.7M−30% | $71.6M−17% | $119.7M−1% | $43.8M−21% |
| −$875K | $13.3M−36% | $23.5M+10% | $10.5M+43% | $868K | $18M+36% | $28M+19% | $9M−15% | −$8M | $17.9M−0% | $24.2M−14% | $14.6M+63% | |
| Net income | $9.2M−67% | $67M−16% | $97.8M+2% | $38.4M+134% | $58.6M+538% | $67.8M+1% | $91.8M−6% | $46.1M+20% | $49.3M−16% | $53.3M−21% | $94.9M+3% | $28.6M−38% |
| $0.09−68% | $0.69−16% | $1.01+3% | $0.40+135% | $0.60+567% | $0.70+1% | $0.94−7% | $0.48+20% | $0.51−15% | $0.55−21% | $0.99+5% | $0.30−38% | |
| 98.2M−1% | 97.4M+0% | 96.9M−1% | 97M−1% | 97.1M−1% | 97.1M−0% | 97.5M+1% | 96.9M−0% | 97.3M+0% | 96.5M−1% | 95.5M−2% | 94.5M−3% |
EPS, diluted: 9 periods, Q4 FY09 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 6 periods, Q4 FY09 to Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Asset Management nearest Dolby Laboratories' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| DLBDolby Laboratories | $5.9B | 26.7× | 31.2× | 4.3× | +1% | 16.7% | |
| VCTRVictory Capital | $6.6B | 19.7× | 12.0× | 4.2× | +52% | 29.6% | |
| HASIHA Sustainable Infrastructure Capital | $4.7B | 67.3× | 35.3× | 13.1× | +27% | 24.1% | |
| HLNEHamilton Lane INC | $4.5B | 12.5× | 30.0× | 5.3× | +24% | 32.1% | |
| MCMoelis | $4.3B | 19.0× | 22.1× | n/m | n/m | n/m | |
| FHIFederated Hermes | $4.2B | 10.6× | 11.7× | 2.2× | +15% | 21.3% | |
| LAZLazard | $4.1B | 18.2× | 14.3× | 1.2× | +6% | 6.9% | |
| MORNMorningstar | $8.4B | 21.3× | 39.7× | 3.3× | +9% | 16.4% | |
| IDCCInterDigital | $8.4B | 37.7× | 23.0× | 10.7× | −12% | 38.3% | |
| HLIHoulihan Lokey | $9.2B | 22.0× | 21.4× | 3.6× | +2% | 16.1% | |
| CNSCohen & Steers | $3.7B | 21.8× | 21.9× | 6.3× | +7% | 28.8% | |
| Peer median | $4.6B | 20.5× | 22.0× | 4.2× | +9% | 24.1% |
More on Dolby Laboratories
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
Its groups
About
- Industry
- Asset Management
- Sector
- Financial Services
Valuation data, not investment advice. Prices as of .